Assessing the effect of genetic markers on drug immunogenicity from a mechanistic model-based approach
Open Access
- 20 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Medical Research Methodology
- Vol. 20 (1), 1-10
- https://doi.org/10.1186/s12874-020-00941-z
Abstract
With the growth in use of biotherapic drugs in various medical fields, the occurrence of anti-drug antibodies represents nowadays a serious issue. This immune response against a drug can be due either to pre-existing antibodies or to the novel production of antibodies from B-cell clones by a fraction of the exposed subjects. Identifying genetic markers associated with the immunogenicity of biotherapeutic drugs may provide new opportunities for risk stratification before the introduction of the drug. However, real-world investigations should take into account that the population under study is a mixture of pre-immune, immune-reactive and immune-tolerant subjects. In this work, we propose a novel test for assessing the effect of genetic markers on drug immunogenicity taking into account that the population under study is a mixed one. This test statistic is derived from a novel two-part semiparametric improper survival model which relies on immunological mechanistic considerations. Simulation results show the good behavior of the proposed statistic as compared to a two-part logrank test. In a study on drug immunogenicity, our results highlighted findings that would have been discarded when considering classical tests. We propose a novel test that can be used for analyzing drug immunogenicity and is easy to implement with standard softwares. This test is also applicable for situations where one wants to test the equality of improper survival distributions of semi-continuous outcomes between two or more independent groups.Keywords
This publication has 18 references indexed in Scilit:
- Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides—Harmonized Terminology and Tactical RecommendationsThe AAPS Journal, 2014
- Evaluation of Pre-existing Antibody Presence as a Risk Factor for Posttreatment Anti-drug Antibody Induction: Analysis of Human Clinical Study Data for Multiple BiotherapeuticsThe AAPS Journal, 2013
- Pre-Existing Biotherapeutic-Reactive Antibodies: Survey Results Within the American Association of Pharmaceutical ScientistsThe AAPS Journal, 2013
- Immunogenicity of Biopharmaceuticals: Causes, Methods to Reduce Immunogenicity, and BiosimilarsPublished by Springer Science and Business Media LLC ,2008
- Flexible Cure Rate Modeling Under Latent Activation SchemesJournal of the American Statistical Association, 2007
- A simple procedure for estimating the false discovery rateBioinformatics, 2004
- Estimating Cure Rates From Survival DataJournal of the American Statistical Association, 2003
- Comparisons of two‐part models with competitorsStatistics in Medicine, 2001
- Partial likelihoodBiometrika, 1975
- Theory and Applications of Hazard Plotting for Censored Failure DataTechnometrics, 1972